|
Non-Small Cell Lung Carcinoma
|
0.380 |
AlteredExpression
|
disease |
BEFREE |
We evaluated glucose transporter type 1 (GLUT1) and carbonic anhydrase IX (CAIX) expression, together with volume-based<sup>18</sup>F-fluorodeoxyglucose positron emission tomography (FDG-PET) parameters, in non-small cell lung cancer (NSCLC) patients, and examined the prognostic significance of those parameters according to its histologic subtype.
|
28212997 |
2017 |
|
Non-Small Cell Lung Carcinoma
|
0.380 |
Biomarker
|
disease |
BEFREE |
<b>Methods</b>: In this study, we evaluated for the first time the prognostic value of Plk1 mRNA and protein expression in combination with the <i>TP53</i> mutation status (next generation sequencing), induction of apoptotic cell death (immunohistochemistry for cleaved caspase 3) and hypoxia (immunohistochemistry for carbonic anhydrase IX (CA IX)) in 98 NSCLC adenocarcinoma patients.
|
28638459 |
2017 |
|
Non-Small Cell Lung Carcinoma
|
0.380 |
AlteredExpression
|
disease |
BEFREE |
Standard immunohistochemical techniques were used to study CA IX expression in 175 resected NSCLC tumors.
|
12560438 |
2003 |
|
Non-Small Cell Lung Carcinoma
|
0.380 |
AlteredExpression
|
disease |
BEFREE |
Quantitative analysis of carbonic anhydrase IX mRNA in human non-small cell lung cancer.
|
16513206 |
2006 |
|
Non-Small Cell Lung Carcinoma
|
0.380 |
Biomarker
|
disease |
BEFREE |
CAIX might be a relevant prognostic marker in early stage NSCLC.
|
29845746 |
2018 |
|
Non-Small Cell Lung Carcinoma
|
0.380 |
Biomarker
|
disease |
BEFREE |
To assess the prognostic importance of carbonic anhydrase IX (CA IX), a hypoxic biomarker, after neoadjuvant treatment in Stage III non-small cell lung cancer (NSCLC) patients.
|
30029935 |
2018 |
|
Non-Small Cell Lung Carcinoma
|
0.380 |
AlteredExpression
|
disease |
BEFREE |
In the present study we measured the mRNA expression of FL and AS CAIX isoforms in 101 NSCLC and in paired not affected tissues.
|
19022520 |
2009 |
|
Non-Small Cell Lung Carcinoma
|
0.380 |
Biomarker
|
disease |
CTD_human |
p53 mutants cooperate with HIF-1 in transcriptional regulation of extracellular matrix components to promote tumor progression.
|
30381462 |
2018 |
|
Non-Small Cell Lung Carcinoma
|
0.380 |
AlteredExpression
|
disease |
BEFREE |
The objective of this study was to investigate PD-L1 expression and its correlation with hypoxic-inducible factor 1α (HIF1A), vascular endothelial growth factor A (VEGFA), glucose transporter 1 (GLUT1), and carbonic anhydrase 9 (CAIX) expression in NSCLC patients.
|
30797490 |
2019 |
|
Noninfiltrating Intraductal Carcinoma
|
0.330 |
AlteredExpression
|
disease |
BEFREE |
In non-BRCA mutation-related cases the expression of the hypoxia markers in DCIS matched the expression in the invasive part in 46% or more of the cases.Although BRCA1 and BRCA2 germline mutation-related invasive breast cancers are different in many ways, the hypoxia-related proteins HIF-1α, CAIX and Glut-1 are expressed in both DCIS and invasive lesions of BRCA1 and BRCA2 mutation carriers.
|
23409121 |
2013 |
|
Noninfiltrating Intraductal Carcinoma
|
0.330 |
Biomarker
|
disease |
CTD_human |
GLUT1 and CAIX were expressed only in DCIS (56.8% and 25.0%) and IDC (44.1% and 30.5%), with higher expression in high grade DCIS than low/intermediate grade DCIS (79.2% vs. 30.0%, p = 0.001 and 37.5% vs. 10.0%, p = 0.036, respectively).
|
20526721 |
2010 |
|
Noninfiltrating Intraductal Carcinoma
|
0.330 |
AlteredExpression
|
disease |
BEFREE |
CAIX overexpression was observed in 16.7% (3/18) of pure DCIS, in 37.9% (22/58) of DCIS-AIC and in 24.1% (14/58) of IC cases (n.s.).
|
31653758 |
2020 |
|
Noninfiltrating Intraductal Carcinoma
|
0.330 |
AlteredExpression
|
disease |
BEFREE |
GLUT1 and CAIX were expressed only in DCIS (56.8% and 25.0%) and IDC (44.1% and 30.5%), with higher expression in high grade DCIS than low/intermediate grade DCIS (79.2% vs. 30.0%, p = 0.001 and 37.5% vs. 10.0%, p = 0.036, respectively).
|
20526721 |
2010 |
|
Ductal Carcinoma
|
0.320 |
AlteredExpression
|
disease |
BEFREE |
Two of these markers were cell surface carbonic anhydrase isozymes (CAIX and/or CAXII) and were validated for protein expression by immunohistochemistry of patient tissue samples on a breast cancer tissue microarray containing 47 normal breast tissue samples, 42 ductal carcinoma in situ, 43 invasive ductal carcinomas without metastasis, 46 invasive ductal carcinomas with metastasis, and 49 lymph node macrometastases of breast carcinoma.
|
22016510 |
2012 |
|
Ductal Carcinoma
|
0.320 |
AlteredExpression
|
disease |
BEFREE |
Immunohistochemical analysis of 53 invasive ductal carcinomas and their autologous metastatic lesions revealed an inverse correlation for the expression of HSulf-1 to CAIX in both the primary tumors (P ≥ 0.0198) and metastatic lesions (P ≥ 0.0067), respectively, by χ(2) test.
|
21266348 |
2011 |
|
Ductal Carcinoma
|
0.320 |
Biomarker
|
disease |
CTD_human |
Hypoxia and metabolic phenotypes during breast carcinogenesis: expression of HIF-1alpha, GLUT1, and CAIX.
|
20526721 |
2010 |
|
Anaplasia
|
0.310 |
Biomarker
|
disease |
CTD_human |
Expression of hypoxia-inducible factor 1 alpha in thyroid carcinomas.
|
19808899 |
2010 |
|
Anaplasia
|
0.310 |
Biomarker
|
disease |
BEFREE |
These data are consistent with the concept, that "aberrant" CAIX staining - meaning absent or weak staining in a cancer expected to have a high level CAIX expression such as clear cell RCC or detectable CAIX expression in tumors that are typically CAIX negative such as papillary and chromophobe RCC - reflects biologic tumor dedifferentiation.
|
30322727 |
2018 |
|
Myeloid Leukemia, Chronic
|
0.310 |
AlteredExpression
|
disease |
BEFREE |
Several LAAs are expressed in CML and therefore are candidate structures for specific immunotherapies: bcr-abl (100%), G250 (24%), hTERT (53%), MPP11 (91%), NEWREN60 (94%), PRAME (62%), Proteinase3 (71%), RHAMM/CD168 (83%), and WT1 (53%), but not BAGE, MAGE-A1, SSX2, or NY-ESO-1.
|
17157168 |
2006 |
|
Myeloid Leukemia, Chronic
|
0.310 |
Biomarker
|
disease |
CTD_human |
Several LAAs are expressed in CML and therefore are candidate structures for specific immunotherapies: bcr-abl (100%), G250 (24%), hTERT (53%), MPP11 (91%), NEWREN60 (94%), PRAME (62%), Proteinase3 (71%), RHAMM/CD168 (83%), and WT1 (53%), but not BAGE, MAGE-A1, SSX2, or NY-ESO-1.
|
17157168 |
2006 |
|
Atypical Ductal Breast Hyperplasia
|
0.300 |
Biomarker
|
disease |
CTD_human |
Hypoxia and metabolic phenotypes during breast carcinogenesis: expression of HIF-1alpha, GLUT1, and CAIX.
|
20526721 |
2010 |
|
Right Ventricular Hypertrophy
|
0.200 |
Biomarker
|
disease |
RGD |
Changes in the expression and/or activation of regulatory proteins in rat hearts adapted to chronic hypoxia.
|
16714773 |
2006 |
|
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The aim of this study was to examine the relationships of CAIX mRNA expression and s-CAIX levels with clinicopathological parameters and survival of patients with primary breast cancer.
|
23358720 |
2013 |
|
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Peroxisome proliferator activated receptor-α/hypoxia inducible factor-1α interplay sustains carbonic anhydrase IX and apoliprotein E expression in breast cancer stem cells.
|
23372804 |
2013 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
The purpose of this study was to evaluate plasma levels of uPAR and CAIX and the effect of anthracycline-based chemotherapy on these biomarkers in patients with operable breast cancer.
|
29893327 |
2018 |